| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3499 |
| Trial ID | NCT05932173 |
| Disease | B-Cell Leukemia | B-Cell Lymphoma | B-Cell Tumor |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | OlyCAR-019 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | An Open Label, Single-site, Dose-escalation Study Aiming to Evaluate the Efficacy and Safety of Anti-CD19 CAR-T Manufactured by OlyCAR Platform(OlyCAR-019) in the Treatment of Relapsed/ Refractory(r/r) B-Cell Malignancies |
| Year | 2023 |
| Country | China |
| Company sponsor | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China |
| Other ID(s) | KM-PBC920 |
| Cohort 1 | |||||||||||
|
|||||||||||